@article{9a5b95c363b74df3afe16958cfcca124,
title = "Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review",
abstract = "Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research.",
keywords = "acute coronary syndromes, calcification, chronic kidney disease, coronary artery disease, revascularization",
author = "{Conference Participants} and Sarnak, {Mark J.} and Kerstin Amann and Sripal Bangalore and Cavalcante, {Jo{\~a}o L.} and Charytan, {David M.} and Craig, {Jonathan C.} and Gill, {John S.} and Hlatky, {Mark A.} and Jardine, {Alan G.} and Ulf Landmesser and Newby, {L. Kristin} and Herzog, {Charles A.} and Michael Cheung and Wheeler, {David C.} and Winkelmayer, {Wolfgang C.} and Marwick, {Thomas H.} and Debasish Banerjee and Carlo Briguori and Chang, {Tara I.} and Chen, {Chien Liang} and deFilippi, {Christopher R.} and Xiaoqiang Ding and Ferro, {Charles J.} and Jagbir Gill and Mario G{\"o}ssl and Isbel, {Nicole M.} and Hideki Ishii and Jardine, {Meg J.} and Kalra, {Philip A.} and G{\"u}nther Laufer and Lentine, {Krista L.} and Kevin Lobdell and Lok, {Charmaine E.} and London, {G{\'e}rard M.} and Jolanta Ma{\l}yszko and Mark, {Patrick B.} and Mohamed Marwan and Yuxin Nie and Parfrey, {Patrick S.} and Roberto Pecoits-Filho and Helen Pilmore and Qunibi, {Wajeh Y.} and Paolo Raggi and Marcello Rattazzi and Patrick Rossignol and Josiah Ruturi and Charumathi Sabanayagam and Shanahan, {Catherine M.} and Shroff, {Gautam R.} and Rukshana Shroff",
note = "Funding Information: The conference was sponsored by Kidney Disease: Improving Global Outcomes and was supported in part by unrestricted educational grants from Akebia Therapeutics, Amgen, Boehringer Ingelheim, Corvidia, Daiichi-Sankyo, Fresenius Medical Care, Kyowa Kirin, and Suntop Healthcare Corp. Dr. Sarnak has served on the Steering Committee of Akebia; has received consulting fees paid to his institution from Akebia; and has served on the Advisory Board of Bayer. Dr. Bangalore has received consultant or advisory grants from Abbott Vascular, Amgen, Biotronik, Pfizer, and Reata. Dr. Cavalcante has had consultant relationships with Abbott Vascular and Boston Scientific; and has received research grant support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, and Siemens. Dr. Charytan has had consultant relationships with Allena, Amgen, AstraZeneca, Daiichi-Sankyo, Fresenius, Janssen, Medtronic/Corvidien, Merck, Novo Nordisk, and Zoll Medical; has received honoraria from Fresenius; and has received research grants from Medtronic and the National Institutes of Health (NIH). Dr. Hlatky has served as a Clinical Event Adjudicator for Tricida. Dr. Landmesser has received honoraria from Amgen, Bayer, The Medicines Company, and Sanofi. Dr. Newby has received consulting fees from Biokier and Roche Diagnostics; has served on the Advisory Boards of Metanomics and Ortho Clinical Diagnostics; and has received research grants paid to her institution from Amylin and Boehringer Ingelheim. Dr. Herzog has received consulting fees from AbbVie, Amgen, AstraZeneca, Corvidia, DiaMedica, FibroGen, Janssen, Oxford University, OxThera, Pfizer, and Relypsa; has stock equity in Boston Scientific, General Electric, Johnson & Johnson, and Merck; has received research grants from Amgen, Bristol-Myers Squibb, National Institute of Diabetes and Digestive and Kidney Diseases/NIH, National Heart, Lung, and Blood Institute/NIH, Relypsa, and the University of British Columbia; has received honoraria from the American College of Cardiology; and has received author royalties from UpToDate. Dr. Wheeler has received consulting fees from Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Janssen, Napp/Mundipharma, and Vifor Fresenius Medical Care Renal Pharma; and has received honoraria from Astellas, Boehringer Ingelheim, Janssen, Mitsubishi Tanabe, Ono Pharmaceutical, and Pharmacosmos. Dr. Winkelmayer has received consulting fees and honoraria from Akebia/Otsuka, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and Vifor Fresenius Medical Care Renal Pharma. Dr. Marwick has received research grants from GE Medical Systems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Steven Weisbord, MD, MSc, served as Guest Associate Editor for this paper. Publisher Copyright: {\textcopyright} 2019 The Authors",
year = "2019",
month = oct,
day = "8",
doi = "10.1016/j.jacc.2019.08.1017",
language = "English (US)",
volume = "74",
pages = "1823--1838",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "14",
}